2023 World Conference on Lung Cancer (Posters)-P2.14. Updated Results of Camrelizumab Plus Nab-Paclitaxel and Carboplatin as First-Line Treatment for ES-SCLC: A Phase II Trial

P2.14. Updated Results of Camrelizumab Plus Nab-Paclitaxel and Carboplatin as First-Line Treatment for ES-SCLC: A Phase II Trial - PDF(Slides)

Back to course

Pdf Summary

A phase II trial evaluated the efficacy and safety of camrelizumab, a PD-1 antibody, in combination with nab-paclitaxel and carboplatin as first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC). The study included 60 patients who received the treatment and were followed from April 2021 to March 2023. The primary endpoint of the trial was the progression-free survival (PFS) rate at 6 months. Secondary endpoints included PFS, objective response rate (ORR), overall survival (OS), and safety. <br /><br />The results showed promising efficacy and a manageable safety profile for the combination therapy. Of the 55 patients who had post-baseline efficacy assessments, 51 achieved an objective response, including 1 complete response and 41 confirmed partial responses. The confirmed ORR was 76.3%, and the unconfirmed ORR was 92.7%. The disease control rate (DCR) was 98.2%. The median duration of response was 6.8 months. The 6-month PFS rate was 50%, and the median PFS was 6.03 months. The median OS was 18.3 months. <br /><br />In terms of safety, 56.7% of patients experienced grade 3 or 4 adverse events, with the most common being neutropenia, leukopenia, thrombocytopenia, increased bilirubin, and increased gamma-glutamyl transferase. <br /><br />Overall, the combination of camrelizumab, nab-paclitaxel, and carboplatin showed promising efficacy in the first-line treatment of ES-SCLC with a manageable safety profile.

Asset Subtitle

Shengxiang Ren

Meta Tag

Speaker Shengxiang Ren

Topic SCLC & Neuroendocrine Tumors: First Line Therapy

Keywords

camrelizumab

PD-1 antibody

nab-paclitaxel

carboplatin

extensive-stage small-cell lung cancer

efficacy

safety

progression-free survival

objective response rate

adverse events